Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis

NCT ID: NCT05090982

Last Updated: 2021-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-31

Study Completion Date

2022-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis/Objective : Patient-centered health care and shared decision making are key components of increasing importance which are recommended by the French Haute Autorite de Sante (HAS) and World Health Organization (WHO).

In the context of dermatology and atopic dermatitis, European guidelines has promoted an active involvement from both patients and caregivers in therapeutic decisions at all stages to achieve therapeutic success and the Task Force on Atopic Dermatitis (ETFAD) has promoted the setting of treatment goals in a shared decision with the patient.

The main objective of this study is to develop and cross culturally validate a tool dedicated to shared-decision in atopic dermatitis that can be used during routine dermatological consultations.

The second objective is to better characterize patients seen in this context and to evaluate patients' satisfaction when empowered by shared decision.

Method : We aim to develop a SDMt in AD following the recommendations of the International Patient Decision Aid Standards (IPDAS) collaboration. Development will use a multistep approach: 1) identification of priority domains for patients; 2) Selection of domains to be included in the SDMt for AD; and 3) Creation and testing of the SDMt.

Participants will be consecutive adult (\>18 years old) patients attending consultation for a AD in medical centres in France (Toulouse, Nantes and Créteil). All participants will provide written consent to participate. The study will be submitted for approbation to the local ethics committees of the University Hospital Centres of Paris and will be conducted according to the Declaration of Helsinki.

Step 1: Identification of priority domains for patients

Step 2: Selection of domains to be included in the SDMt for AD

Step 3: Creation and testing of the SDMt

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atopic Dermatitis shared medical decision-making tool e-Delphi

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Atopic dermatitis

150 patients with Atopic dermatitis

Audio recordings during the consultations

Intervention Type OTHER

50 patients with audio recordings of the consultation

Audio recordings during the consultations and test of the shared medical decision-making tool for modification

Intervention Type OTHER

50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification

Audio recordings during the consultations and test of the shared medical decision-making tool for validation

Intervention Type OTHER

50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Audio recordings during the consultations

50 patients with audio recordings of the consultation

Intervention Type OTHER

Audio recordings during the consultations and test of the shared medical decision-making tool for modification

50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification

Intervention Type OTHER

Audio recordings during the consultations and test of the shared medical decision-making tool for validation

50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years, male or female.
* Patient with atopic dermatitis
* Written information given to the patient and no objection from the patient to participate to the study

Exclusion Criteria

* Patient under guardianship or curatorship
* Patient with cognitive dysfunction that makes it impossible to communicate effectively or to complete the questionnaire
* Patient under AME
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre-André Natella, PhD

Role: STUDY_DIRECTOR

Assistance Publique - Hôpitaux Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Henri Mondor

Créteil, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Khaled Ezzedine, MD

Role: CONTACT

Phone: (0)149812504

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Khaled Ezzedine, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A01859-32

Identifier Type: REGISTRY

Identifier Source: secondary_id

APHP211198

Identifier Type: -

Identifier Source: org_study_id